First U.S. Patient Receives Advanced Heart Monitoring Device

First Patient in U.S. Benefits from New Heart Monitoring Technology

An exciting milestone has been achieved in Cincinnati, where a patient became the first in the United States to receive the innovative V-LAP system for heart monitoring, developed by Vectorious Medical Technologies. This advanced system allows for remote monitoring of heart congestion and the self-adjustment of diuretics, providing heart failure patients with greater control over their condition.

The V-LAP system includes a tiny sensor that is implanted into the heart using a minimally invasive procedure. This sensor measures Left Atrial Pressure (LAP), offering accurate and early detection of fluid overload. This vital information enables patients and their doctors to manage heart failure more proactively.

Improving Heart Failure Management

The first U.S. implantation of the V-LAP system was performed by Dr. Sitaramesh Emani at The Christ Hospital in Cincinnati. With 56 implantations done so far, accumulating over 40,000 days of monitoring data, this technology promises to revolutionize heart failure management by reducing hospitalizations and improving patients' quality of life.

Dr. Emani highlighted the importance of this development, emphasizing that real-time LAP monitoring enables a more personalized approach to treatment. Patients can actively manage their care, resulting in fewer hospital visits and a better understanding of their condition.

Promising Clinical Results

Initial studies, published in the European Journal of Heart Failure, show that the V-LAP system allows 85% of patients to manage their condition independently without frequent physician intervention. This has led to a significant reduction in heart failure-related hospital admissions and notable improvements in patients' quality of life.

The success of the V-LAP system in Europe and Israel has laid the groundwork for its introduction in the U.S., with ongoing clinical trials scheduled to further validate these positive outcomes.

Looking Ahead

Vectorious Medical Technologies is committed to expanding this innovative heart monitoring system in the U.S. and working closely with medical professionals, regulatory agencies, and partners to ensure its widespread adoption. The company's CEO, Dr. Eyal Orion, believes that this technology could reverse the troubling trends in cardiovascular mortality rates.

Dr. Orion is optimistic that the data from ongoing and future studies will support the widespread use of the V-LAP system, helping more heart failure patients manage their condition effectively and enjoy a better quality of life.

About Vectorious Medical Technologies

Vectorious Medical Technologies, based in Tel Aviv, was founded in 2011 with the mission to empower heart failure patients through innovative medical technology. The company's V-LAP system helps patients monitor their heart's pressure, detect early fluid buildup, and manage their condition with greater ease.

For more information about Vectorious Medical Technologies and their groundbreaking work, visit their website or contact Lili Arbely-Elbaz at +972-(0)525909192 or [email protected].